<DOC>
	<DOCNO>NCT00283608</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient cancer receive anastrozole may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor learn anastrozole work body . PURPOSE : This research study look pharmacogenetics anastrozole postmenopausal woman estrogen receptor-positive ( ER+ ) and/or progesterone receptor-positive ( PR+ ) stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Pharmacogenetics Anastrozole Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate association intragenic haplotype gene encode protein involve anastrozole metabolism pathway anastrozole steady state plasma level postmenopausal woman estrogen receptor-positive and/or progesterone receptor-positive stage I , II , III breast cancer . - To evaluate association intragenic haplotype gene encode protein involve pathway estrogen synthesis , metabolism , transport gene involve anastrozole metabolism pharmacodynamic ( PD ) effect anastrozole therapy , measure change ( vs drug therapy ) plasma level estradiol , estrone , estrone sulfate , testosterone , androstenedione patient . - To evaluate association intragenic haplotype describe PD effect anastrozole therapy , measure change breast density bone mineral density 1 year drug therapy . - To collect bank blood sample mammographic , bone density , questionnaire data patient enrol CAN-NCIC-MA27 randomize receive exemestane . OUTLINE : This multicenter study . Patients stratify accord prior tamoxifen use ( yes v ) . Blood sample obtain pharmacogenetic study baseline , 6-12 week , 1 year . Samples analyze plasma anastrozole concentration via high-performance liquid chromatography ; genotyping htSNPs via PCR ; plasma level estradiol , estrone , estrone sulfate , testosterone , androstenedione via gas chromatographic negative chemical ionization tandem mass spectrometry liquid chromatographic electrospray tandem mass spectrometry . Mammograms obtain baseline ( i.e. , within past 6 month ) 1 year ass breast density . Patients bilateral disease , bilateral breast augmentation , bilateral mastectomy participate portion study . Patients Mayo Clinic Cancer Center Rochester site also undergo bone mineral density measurement via dual x-ray absorptiometry baseline 1 year . Metabolic markers bone formation resorption also assess Mayo Clinic patient . Blood sample mammographic , bone mineral density , questionnaire data collect patient randomized receive exemestane CAN-NCIC-MA27 store future study . Patients complete questionnaire baseline , 6-12 week , 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Stage I , II , III disease Resected disease Planning undergo treatment anastrozole clinically approve dose 1 mg/day OR Mayo Clinic Cancer Center Rochester patient enrol enrolled CANNCICMA27 start take study medication ( anastrozole exemestane ) Hormone receptor status : Estrogen receptorpositive and/or progesterone receptorpositive primary tumor PATIENT CHARACTERISTICS : Female Postmenopausal Able complete questionnaire alone assistance PRIOR CONCURRENT THERAPY : More 6 month since prior endocrine therapy , except tamoxifen No prior aromatase inhibitor ( e.g. , letrozole exemestane ) No prior ovarian function suppression surgery radiotherapy , ovarian ablation , luteinizing hormonereleasing hormone analogue ( e.g. , goserelin ) treatment cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>